The ""Oncosimulator"": A multilevel, clinically oriented simulation system of tumor growth and organism response to therapeutic schemes. Towards the clinical evaluation of in silica oncology

Stamatakos, GS; Dionysiou, DD; Graf, NM; Sofra, NA; Desmedt, C; Hoppe, A; Uzunoglu, NK; Tsiknakis, M

dc.contributor.author	Stamatakos, GS	en
dc.contributor.author	Dionysiou, DD	en
dc.contributor.author	Graf, NM	en
dc.contributor.author	Sofra, NA	en
dc.contributor.author	Desmedt, C	en
dc.contributor.author	Hoppe, A	en
dc.contributor.author	Uzunoglu, NK	en
dc.contributor.author	Tsiknakis, M	en
dc.date.accessioned	2014-03-01T02:44:58Z
dc.date.available	2014-03-01T02:44:58Z
dc.date.issued	2007	en
dc.identifier.issn	05891019	en
dc.identifier.uri	https://dspace.lib.ntua.gr/xmlui/handle/123456789/32060
dc.subject	Cancer Treatment	en
dc.subject	Clinical Evaluation	en
dc.subject	European Commission	en
dc.subject	in silico	en
dc.subject	Software Tool	en
dc.subject	Tumor Growth	en
dc.subject	Breast Cancer	en
dc.subject	Integrated Project	en
dc.subject.other	Computer aided software engineering	en
dc.subject.other	Oncology	en
dc.subject.other	Optimization	en
dc.subject.other	Silica	en
dc.subject.other	Tumors	en
dc.subject.other	Clinically oriented simulation system	en
dc.subject.other	Tumor growth	en
dc.subject.other	Cell growth	en
dc.title	The ""Oncosimulator"": A multilevel, clinically oriented simulation system of tumor growth and organism response to therapeutic schemes. Towards the clinical evaluation of in silica oncology	en
heal.type	conferenceItem	en
heal.identifier.primary	10.1109/IEMBS.2007.4353879	en
heal.identifier.secondary	http://dx.doi.org/10.1109/IEMBS.2007.4353879	en
heal.identifier.secondary	4353879	en
heal.publicationDate	2007	en
heal.abstract	The ""Oncosimulator"" is at the same time a concept of multilevel integrative cancer and (treatment affected) normal tissue biology, an algorithmic construct and a software tool which aims at supporting the clinician in the process of optimizing cancer treatment on the patient individualized basis. Additionally it is a platform for better understanding and exploring the natural phenomenon of cancer as well as training doctors and interested patients alike. In order to achieve all of these goals it has to undergo a thorough clinical optimization and validation process. This is one of the goals of the European Commission funded integrated project ""ACGT: Advancing Clinicogenomic Trials on Cancer"". Nephroblastoma (Wilms' tumor) and breast cancer have been selected to serve as two paradigms to clinically specify and evaluate the ""Oncosimulator"" as well as the emerging domain of in silico oncology. ©2007 IEEE.	en
heal.journalName	Annual International Conference of the IEEE Engineering in Medicine and Biology - Proceedings	en
dc.identifier.doi	10.1109/IEMBS.2007.4353879	en
dc.identifier.volume	2007	en
dc.identifier.spage	6628	en
dc.identifier.epage	6631	en